Lithuania and IBM will share equal rights to the intellectual property, and R&D commercialization, such as patents, IP licenses, products and prototypes that result from the research center's activities.
The Lithuanian research center also will involve scientists from Lithuanian universities (Vilnius University, Kaunas University of Technology, Kaunas University of Medicine) who are focused on developing innovations that will contribute to the development of a knowledge-based society in Lithuania, and will enable the Lithuanian research center to become a focal point for healthcare, life sciences, and nanotechnology in the Baltic region.
In the area of nanotechnology, IBM and Lithuanian scientists will focus on integrated photonics and novel photonic materials for faster computers of the future and nanopatterning security tags for advanced anti-forgery technology at IBM's new, state-of-the-art nanotechnology center in Switzerland that opens next year.
Researchers from IBM's lab in Haifa, Israel will partner with Lithuanian scientists on a variety of healthcare projects that will aim to provide a better understanding of how to diagnose and treat life-threatening diseases, such as cardiovascular disease.
The Government of Lithuania hopes this new partnership will help the national science to compete more successfully in commercial markets. Each year a number of scientific discoveries are registered in Lithuania, but only a limited few later translate into patents and are applied in commercial activity.
In 2009, Lithuania spent more than 700 million Litas (roughly more than 200 million euros) on research and development, while only 13 applications were filed to receive European Patent.
Lithuania
